The full-year 2013 BioMeter analysis shows across-the-board increases in BioMeter value, with an average of $33.9 million for all transactions, up from approximately $21.2 million in 2012. Increases occurred for each stage of development, with the BioMeter for preclinical/discovery transactions averaging approximately $21.8 million in 2013, compared to approximately $10 million in 2012; the BioMeter value for Phase 1 products averaging approximately $40 million in 2013 compared to approximately $10 million in 2012; the BioMeter value for Phase 2 products increasing to approximately $47.4 million in 2013 from approximately $37.1 million in 2012; the BioMeter value for Phase 3 products increasing to approximately $46.2 million in 2013 from approximately $24.6 million in 2012; and the BioMeter value for approved products increasing to approximately $50.6 million in 2013 from approximately $27 million in 2012.
This data shows strength for sellers/licensors across all stages of the drug development spectrum. Indeed, the only reason that the overall average BioMeter did not jump more compared to 2012 is because of the mix of transactions. In 2013, preclinical/discovery transactions accounted for approximately 48% of transactions reporting up-front payments and reporting stage of development, compared to approximately 38% of transactions in 2012.
Please see full issue below for more information.
Firefox recommends the PDF Plugin for Mac OS X for viewing PDF documents in your browser.
We can also show you Legal Updates using the Google Viewer; however, you will need to be logged into Google Docs to view them.
Please choose one of the above to proceed!
LOADING PDF: If there are any problems, click here to download the file.